Welcome to our dedicated page for Roche Hldg news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Hldg stock.
Roche Holding Ltd. (RHHBY) reports healthcare developments across medicines, diagnostics and digital health, including updates from Genentech as a member of the Roche Group. Recurring news covers operating and financial results, regional sales trends, product performance and regulatory disclosures tied to the company’s pharmaceutical and diagnostic portfolios.
Company updates frequently feature ophthalmology products and pipeline assets such as Vabysmo, Susvimo and vamikibart across retinal conditions including diabetic macular edema and neovascular age-related macular degeneration. Roche also reports clinical data in neurology and autoimmune disease, including fenebrutinib in multiple sclerosis and ENSPRYNG in myelin oligodendrocyte glycoprotein antibody-associated disease, along with diagnostics approvals and patient-education initiatives.
On February 10, 2023, Roche (OTCQX: RHHBY) announced its Roche Long Term Foundation acquired 540,000 bearer shares through an accelerated book building process. This acquisition is intended to meet both current and future obligations from equity compensation plans. The sale also involved a member of a shareholder group, which sold 2.7 million shares, reducing their ownership from 67.5% to approximately 65% of Roche's total issued shares. Roche continues to be a leader in biotechnology and diagnostics and has been recognized for its sustainability efforts in the pharmaceuticals industry.
Roche reported positive data for Vabysmo (faricimab) from two phase III trials, BALATON and COMINO, evaluating its efficacy for macular edema due to retinal vein occlusion (RVO). In both trials, Vabysmo achieved non-inferior visual acuity gains compared to aflibercept. The studies showed a significant reduction in retinal fluid, indicating effective treatment outcomes. If approved, RVO will be the third indication for Vabysmo, which is already authorized for neovascular age-related macular degeneration and diabetic macular edema. The findings will be submitted for regulatory review globally, including by the FDA and EMA.
Roche (OTC-PINK:RHHBY) has expanded its collaboration with Janssen Biotech to enhance the development of companion diagnostics aimed at personalised healthcare. This new agreement, announced on February 9, 2023, will include a diverse range of technologies such as blood and tissue biomarkers, digital pathology, and next-generation sequencing. The collaboration aims to improve access to targeted treatment options for patients, exemplifying Roche's commitment to precision medicine. Successful projects may include new immunohistochemistry assays and advanced data analysis for patient identification.
Roche has expanded its collaboration with Janssen Biotech to enhance personalized healthcare through the development of companion diagnostics. The agreement includes a wide range of technologies such as immunohistochemistry, digital pathology, and next-generation sequencing. This collaboration aims to improve access to targeted treatment options, thereby strengthening Roche's position in precision medicine. The partnership also looks to explore innovative projects like data analysis and the development of new assays for patient enrollment in personalized treatments.
Genentech, a member of the Roche Group (OTCQX: RHHBY), announced positive results from the Phase III COMMODORE 2 study, evaluating crovalimab for treating paroxysmal nocturnal hemoglobinuria (PNH). The study met its co-primary endpoints, showing crovalimab achieved effective disease control and was non-inferior to the standard of care, eculizumab. Additionally, the COMMODORE 1 study confirmed the favorable benefit-risk profile of crovalimab for patients switching from C5 inhibitors. Genentech plans to submit findings to regulatory authorities worldwide.
Roche announced positive results from the global phase III COMMODORE 2 study, evaluating crovalimab for treating paroxysmal nocturnal haemoglobinuria (PNH). The study met its co-primary efficacy endpoints, showing crovalimab achieved disease control and transfusion avoidance in patients not previously treated with complement inhibitors. The phase III COMMODORE 1 study corroborated the favorable benefit-risk profile of crovalimab for patients switching from current C5 inhibitors. Roche plans to submit the findings to regulatory authorities globally and present results at an upcoming medical meeting.
Roche has appointed Teresa Graham as the new CEO of Roche Pharmaceuticals, effective March 2023. Previously Head of Global Product Strategy, Graham will join the Corporate Executive Committee. Levi Garraway, the Chief Medical Officer, will also become a member of this committee. Both executives will report to the new Roche Group CEO, Thomas Schinecker. Graham brings extensive experience from her tenure at Genentech and has a solid track record in strategic roles. Garraway is renowned for his expertise in cancer genomics and has contributed significantly to the field. These changes reflect Roche's commitment to strong leadership as it continues to focus on innovation.
Roche's group sales grew by 2% at constant exchange rates, totaling CHF 63.3 billion in 2022, despite a decline in COVID-19-related sales. The Pharmaceuticals Division saw a 2% increase in sales, bolstered by strong performance from newer medicines, while the Diagnostics Division grew by 3%.
Core earnings per share rose by 5%, but IFRS net income dropped by 6% to CHF 13.5 billion. Looking ahead, Roche anticipates low single-digit sales decline due to a projected CHF 5 billion drop in COVID-19 product sales, while new product launches suggest potential for solid growth.
Roche has announced that the European Commission approved the expansion of the marketing authorization for Hemlibra (emicizumab), allowing it to be used as a prophylactic treatment for moderate haemophilia A. This approval, based on results from the HAVEN 6 trial, demonstrates Hemlibra's effective bleed control and favorable safety profile for patients without factor VIII inhibitors. Currently, around 900,000 people are affected by haemophilia A globally, with approximately 14% having a moderate form. The goal of this approval is to help improve quality of life for those with moderate disease, many of whom currently lack effective prophylactic treatment options.
Jana Care has partnered with Roche Diagnostics to develop a point-of-care blood testing platform aimed at enhancing remote healthcare access for patients with chronic kidney disease and heart failure. This collaboration focuses on at-home testing capabilities, allowing patients to perform essential blood tests and enabling clinicians to remotely review results. The initiative addresses significant healthcare challenges, considering that over 43 million Americans live with these chronic conditions. The platform is expected to improve disease management and monitoring, providing a much-needed solution to the limitations of current testing methods.